NR1H4 and neoplasm: Ji et al. found that the delivery of obeticholic acid (OCA), a modified bile acid derivative that acts on FXR as an agonist, via nanoapproach significantly suppressed hepatic tumor growth in a murine orthotopic H22 tumor mode by increasing anti-tumor immunity [164].